AlphaCrest Capital Management LLC - BRIDGEBIO PHARMA INC ownership

BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 225 filers reported holding BRIDGEBIO PHARMA INC in Q3 2023. The put-call ratio across all filers is 0.81 and the average weighting 0.6%.

Quarter-by-quarter ownership
AlphaCrest Capital Management LLC ownership history of BRIDGEBIO PHARMA INC
ValueSharesWeighting
Q4 2021$323,000
-20.4%
19,363
+123.4%
0.01%
-42.9%
Q3 2021$406,000
-80.9%
8,668
-75.2%
0.02%
-77.2%
Q2 2021$2,131,000
+186.0%
34,961
+188.9%
0.09%
+119.0%
Q1 2021$745,000
+80.8%
12,100
+108.6%
0.04%
+23.5%
Q4 2020$412,0005,8000.03%
Other shareholders
BRIDGEBIO PHARMA INC shareholders Q3 2023
NameSharesValueWeighting ↓
Aisling Capital Management LP 6,068,125$55,099,00039.31%
M28 Capital Management LP 466,200$4,233,0004.74%
Kohlberg Kravis Roberts & Co. L.P. 31,060,971$282,034,0003.75%
Octagon Capital Advisors LP 933,743$8,478,0002.26%
VIKING GLOBAL INVESTORS LP 26,620,991$241,719,0001.11%
HHLR ADVISORS, LTD. 5,362,014$48,687,0001.04%
Cormorant Asset Management, LP 1,469,179$13,340,0001.01%
Knott David M Jr 213,206$1,936,0000.81%
Fernwood Investment Management, LLC 183,900$1,670,0000.72%
HighVista Strategies LLC 105,942$962,0000.58%
View complete list of BRIDGEBIO PHARMA INC shareholders